Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Chronic Myeloid Leukemia

  • Massimo Breccia
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_1156-6



Chronic myeloid leukemia (CML) is a clonal disorder caused by a malignant transformation of a hematopoietic stem cell. Mature granulocytes and precursors proliferate and increase in bone marrow and peripheral blood.


The annual incidence is 1–2 cases every 100,000 inhabitants/year and increases with age, with a male prevalence. It account for 15–20 % of all cases of leukemia in adult Western population. The disease is characterized by a reciprocal translocation t(9;22) (q34;q11) called Philadelphia chromosome (Ph). The Ph chromosome is present in more than 90 % of adult CML patients, in 15–30 % of adult acute lymphoblastic leukemia (ALL), and in 2 % of acute myeloid leukemia (AML). Diagnosis is often based on morphological analysis of peripheral blood that showed increased mature myeloid cells, eosinophils, and basophils. Characterization of disease is...


Chronic Myeloid Leukemia Hematopoietic Stem Cell Transplantation Chronic Myeloid Leukemia Patient Cytogenetic Response Major Molecular Response 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27:6041–6051CrossRefPubMedGoogle Scholar
  2. Breccia M, Alimena G (2011a) Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients. BioDrugs 25:147–157CrossRefPubMedGoogle Scholar
  3. Breccia M, Alimena G (2011b) Nilotinib for the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia: review of the latest clinical evidence. Clin Investig 1:707–719CrossRefGoogle Scholar
  4. Druker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037CrossRefPubMedGoogle Scholar
  5. Hehlmann R, Hochhaus A, Baccarani M (2007) European LeukemiaNet. Chronic myeloid leukaemia. Lancet 370:342–350CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of Cellular Biotechnologies and HematologySapienza UniversityRomeItaly